Faculty profile

Satyabrata Kar

ResearcherMedicine/NeurologyUniversity of Alberta

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Alberta directory, so their courses may be missing. Find their university profile.

Satyabrata Kar

Researcher

Medicine/Neurology

Health Sciences

University of Alberta

Edmonton, Alberta, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
11 publications in the last five years, latest in 2026.
Senior (last) author on 9 recent papers, a sign of leading a research group.
Principal investigator on 10 research grants (7 CIHR, 3 NSERC), most recently in 2023.
Supervised 1 trainee who won CIHR awards, most recently in 2013.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Neuroprotection Alzheimer'S Disease Animal Models Of Alzheimer'S Disease Neurotoxicity Beta-Amyloid Peptide Cognitive Deficits Induced Pluripotent Stem Cells Protein Aggregation

Latest papers

Native PLGA nanoparticles attenuate disease pathology via multiple pathways in 5xFAD Alzheimer's model.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026 · senior author
Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions.
International journal of nanomedicine · 2025 · senior author
Native PLGA nanoparticles attenuate Aβ-seed induced tau aggregation under in vitro conditions: potential implication in Alzheimer's disease pathology.
Scientific reports · 2024 · senior author

All 32 publications

Latest funding

Native PLGA Nanoparticles for detection and treatment of Alzheimer's Disease
SSHRC · 2024 · Co-investigator
$125,000
Native PLGA nanoparticles attenuate aggregation, phosphorylation and internalization of tau protein: potential implication in the treatment of Alzheimer's disease
CIHR · 2023 · Nominated PI
$990,675
Biodegradable acidic nanoparticles attenuate beta-amyloid aggregation/toxicity: potential implication in the treatment of Alzheimer's disease pathology
CIHR · 2021 · Nominated PI
$730,576

All 12 grants and awards

32 publications.

Native PLGA nanoparticles attenuate disease pathology via multiple pathways in 5xFAD Alzheimer's model.

Karthivashan G, Wang S, Wu Q, Dahal A, Li X, Galleguillos D, Sipione S, Thinakaran G, Kar S

Alzheimer's & dementia : the journal of the Alzheimer's Association2026Senior author

DOI: 10.1002/alz.71348 PMID: 42162953

Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions.

Paul PS, Rathnam M, Khalili A, Cortez LM, Srinivasan M, Planel E, Cho JY, Wille H, Sim VL, Mok SA, Kar S

International journal of nanomedicine2025Senior author

DOI: 10.2147/ijn.s494104 PMID: 39968061

Native PLGA nanoparticles attenuate Aβ-seed induced tau aggregation under in vitro conditions: potential implication in Alzheimer's disease pathology.

Paul PS, Patel T, Cho JY, Yarahmady A, Khalili A, Semenchenko V, Wille H, Kulka M, Mok SA, Kar S

Scientific reports2024Senior author

DOI: 10.1038/s41598-023-50465-x PMID: 38167993

Correction: Predominant expression of Alzheimer's disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts.

De Rossi P, Buggia-Prévot V, Clayton BLL, Vasquez JB, van Sanford C, Andrew RJ, Lesnick R, Botté A, Deyts C, Salem S, Rao E, Rice RC, Parent A, Kar S, Popko B, Pytel P, Estus S, Thinakaran G

Molecular neurodegeneration2023

DOI: 10.1186/s13024-023-00662-z PMID: 37784204

Correction: Detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of Alzheimer's disease.

Govindarajan K, Kar S

Journal of nanobiotechnology2023Senior author

DOI: 10.1186/s12951-023-02009-8 PMID: 37537574

Detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of alzheimer's disease.

Govindarajan K, Kar S

Journal of nanobiotechnology2023Senior author

DOI: 10.1186/s12951-023-01957-5 PMID: 37424018

Administration of Kainic Acid Differentially Alters Astrocyte Markers and Transiently Enhanced Phospho-tau Level in Adult Rat Hippocampus.

Dahal A, Govindarajan K, Kar S

Neuroscience2023Senior author

DOI: 10.1016/j.neuroscience.2023.02.010 PMID: 36805001

Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology.

Anand B, Wu Q, Nakhaei-Nejad M, Karthivashan G, Dorosh L, Amidian S, Dahal A, Li X, Stepanova M, Wille H, Giuliani F, Kar S

Bioactive materials2022Senior author

DOI: 10.1016/j.bioactmat.2022.05.030 PMID: 36330076

Native PLGA nanoparticles regulate APP metabolism and protect neurons against β-amyloid toxicity: Potential significance in Alzheimer's disease pathology.

Wu Q, Karthivashan G, Nakhaei-Nejad M, Anand BG, Giuliani F, Kar S

International journal of biological macromolecules2022Senior author

DOI: 10.1016/j.ijbiomac.2022.08.148 PMID: 36030976

Unconjugated PLGA nanoparticles attenuate temperature-dependent β-amyloid aggregation and protect neurons against toxicity: implications for Alzheimer's disease pathology.

Paul PS, Cho JY, Wu Q, Karthivashan G, Grabovac E, Wille H, Kulka M, Kar S

Journal of nanobiotechnology2022Senior author

DOI: 10.1186/s12951-022-01269-0 PMID: 35120558

Native PLGA Nanoparticles for detection and treatment of Alzheimer's Disease

Co-investigatorSSHRC2024New Frontiers in Research Fund - Exploration

Principal investigators: Serpe, Michael

$125,000

Native PLGA nanoparticles attenuate aggregation, phosphorylation and internalization of tau protein: potential implication in the treatment of Alzheimer's disease

Nominated PICIHR2023Project Grant

Principal investigators: Kar, Satyabrata

Keywords: Alzheimer'S Disease; Animal Models Of Alzheimer'S Disease; Cognitive Deficits; Induced Pluripotent Stem Cells; Native Nanoparticles; Neuroprotection; Neurotoxicity; Protein Aggregation; Protein Disaggregation; Tau Protein

$990,675

Biodegradable acidic nanoparticles attenuate beta-amyloid aggregation/toxicity: potential implication in the treatment of Alzheimer's disease pathology

Nominated PICIHR2021Project Grant

Principal investigators: Kar, Satyabrata

Keywords: Acidic Nanoparticles; Alzheimer'S Disease; Animal Models Of Alzheimer'S Disease; Beta-Amyloid Peptide; Cognitive Deficits; Induced Pluripotent Stem Cells; Lysosomal Leakage; Neuroprotection; Neurotoxicity; Protein Aggregation

$730,576

SIGNIFICANCE OF THE MULTIFUNCTIONAL INSULIN-LIKE GROWTH FACTOR-II RECEPTOR IN REGULATING NORMAL BRAIN FUNCTION

Principal investigatorNSERC2017Discovery Grants Program - Individual

Principal investigators: Kar, Satyabrata

$156,000

Role of lysosomal enzymes cathepsins B and D in neuronal vulnerability: potential implications in Alzheimer's disease pathology

Nominated PICIHR2017Project Grant

Principal investigators: Kar, Satyabrata

Keywords: Alzheimer'S Disease; Amyloid Precursor Protein; Animal Models Of Alzheimer'S Disease; Beta-Amyloid Peptide; Endosomal-Lysosomal System; Lysosomal Leakage; Neuroprotection; Neurotoxicity

$742,050

Role of activated astrocytes in APP metabolism and its functional implications in Alzheimer's disease pathology

Nominated PICIHR2016Project Grant

Principal investigators: Kar, Satyabrata

Keywords: Alzheimer'S Disease; Amyloid Precursor Protein; Animal Models Of Alzheimer'S Disease; Astrocytes; Beta-Amyloid Degrading Enzymes; Beta-Amyloid Peptide; Exosomes; Neuroprotection; Neurotoxicity

$680,850

Phenylalkylhydrazine drugs and treatment of Alzheimer's disease.

SupervisorCIHR2013Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Matveychuk, Dmitriy

Keywords: Alzheimer'S Disease; Drug Development; Neurochemistry; Neurodegenerative Disorders

$105,000

Role of beta-amyloid peptides in kainic acid-induced toxicity and its implications in temporal lobe epilepsy

Nominated PICIHR2012Operating Grant

Principal investigators: Kar, Satyabrata

Keywords: Astrocytes; Beta Amyloid Peptides; Excitotoxicity; Neurodegeneration; Neuroprotection; Temporal Lobe Epilepsy

$396,335

Single transmembrane domain insulin-like growth factor-II receptor and G protein: potential interaction and its significance in brain function

Principal investigatorNSERC2011Discovery Grants Program - Individual

Principal investigators: Kar, Satyabrata

$200,000

Role of beta-amyloid peptides in regulating the function/survival of central cholinergic neurons and its implications in Alzheimer's disease pathology

Nominated PICIHR2009Operating Grant

Principal investigators: Kar, Satyabrata

Keywords: Alzheimer'S Disease; Beta Amyloid Peptides; Cholinergic Neurons; Immunocytochemistry; Neurodegeneration; Neuroprotection

$510,898

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2023

Subject: Prospective PhD student: Neuroprotection Dear Professor Kar, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Native PLGA nanoparticles attenuate disease pathology via multiple pathways in 5xFAD Alzheimer's model." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Native PLGA nanoparticles attenuate aggregation, phosphorylation and internalization of tau protein: potential implication in the treatment of Alzheimer's disease" (2023), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Satyabrata Kar

Research

Latest papers

Latest funding

Native PLGA nanoparticles attenuate disease pathology via multiple pathways in 5xFAD Alzheimer's model.

Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions.

Native PLGA nanoparticles attenuate Aβ-seed induced tau aggregation under in vitro conditions: potential implication in Alzheimer's disease pathology.

Correction: Predominant expression of Alzheimer's disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts.

Correction: Detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of Alzheimer's disease.

Detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of alzheimer's disease.

Administration of Kainic Acid Differentially Alters Astrocyte Markers and Transiently Enhanced Phospho-tau Level in Adult Rat Hippocampus.

Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology.

Native PLGA nanoparticles regulate APP metabolism and protect neurons against β-amyloid toxicity: Potential significance in Alzheimer's disease pathology.

Unconjugated PLGA nanoparticles attenuate temperature-dependent β-amyloid aggregation and protect neurons against toxicity: implications for Alzheimer's disease pathology.

Native PLGA Nanoparticles for detection and treatment of Alzheimer's Disease

Native PLGA nanoparticles attenuate aggregation, phosphorylation and internalization of tau protein: potential implication in the treatment of Alzheimer's disease

Biodegradable acidic nanoparticles attenuate beta-amyloid aggregation/toxicity: potential implication in the treatment of Alzheimer's disease pathology

SIGNIFICANCE OF THE MULTIFUNCTIONAL INSULIN-LIKE GROWTH FACTOR-II RECEPTOR IN REGULATING NORMAL BRAIN FUNCTION

Role of lysosomal enzymes cathepsins B and D in neuronal vulnerability: potential implications in Alzheimer's disease pathology

Role of activated astrocytes in APP metabolism and its functional implications in Alzheimer's disease pathology

Phenylalkylhydrazine drugs and treatment of Alzheimer's disease.

Role of beta-amyloid peptides in kainic acid-induced toxicity and its implications in temporal lobe epilepsy

Single transmembrane domain insulin-like growth factor-II receptor and G protein: potential interaction and its significance in brain function

Role of beta-amyloid peptides in regulating the function/survival of central cholinergic neurons and its implications in Alzheimer's disease pathology

Frequent collaborators

Holger Wille

David Westaway

Sue-Ann Mok

Fabrizio Giuliani

Jack Jhamandas

Emmanuel Planel

Simonetta Sipione

Satyabrata Kar

Research

Latest papers

Latest funding

Native PLGA nanoparticles attenuate disease pathology via multiple pathways in 5xFAD Alzheimer's model.

Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions.

Native PLGA nanoparticles attenuate A&#x3b2;-seed induced tau aggregation under in vitro conditions: potential implication in Alzheimer's disease pathology.

Correction: Predominant expression of Alzheimer's disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts.

Correction: Detection of &#x3b2;-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of Alzheimer's disease.

Detection of &#x3b2;-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of alzheimer's disease.

Administration of Kainic Acid Differentially Alters Astrocyte Markers and Transiently Enhanced Phospho-tau Level in Adult Rat Hippocampus.

Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology.

Native PLGA nanoparticles regulate APP metabolism and protect neurons against &#x3b2;-amyloid toxicity: Potential significance in Alzheimer's disease pathology.

Unconjugated PLGA nanoparticles attenuate temperature-dependent &#x3b2;-amyloid aggregation and protect neurons against toxicity: implications for Alzheimer's disease pathology.

Native PLGA Nanoparticles for detection and treatment of Alzheimer's Disease

Native PLGA nanoparticles attenuate aggregation, phosphorylation and internalization of tau protein: potential implication in the treatment of Alzheimer's disease

Biodegradable acidic nanoparticles attenuate beta-amyloid aggregation/toxicity: potential implication in the treatment of Alzheimer's disease pathology

SIGNIFICANCE OF THE MULTIFUNCTIONAL INSULIN-LIKE GROWTH FACTOR-II RECEPTOR IN REGULATING NORMAL BRAIN FUNCTION

Role of lysosomal enzymes cathepsins B and D in neuronal vulnerability: potential implications in Alzheimer's disease pathology

Role of activated astrocytes in APP metabolism and its functional implications in Alzheimer's disease pathology

Phenylalkylhydrazine drugs and treatment of Alzheimer's disease.

Role of beta-amyloid peptides in kainic acid-induced toxicity and its implications in temporal lobe epilepsy

Single transmembrane domain insulin-like growth factor-II receptor and G protein: potential interaction and its significance in brain function

Role of beta-amyloid peptides in regulating the function/survival of central cholinergic neurons and its implications in Alzheimer's disease pathology

Frequent collaborators

Holger Wille

David Westaway

Sue-Ann Mok

Fabrizio Giuliani

Jack Jhamandas

Emmanuel Planel

Simonetta Sipione

Native PLGA nanoparticles attenuate Aβ-seed induced tau aggregation under in vitro conditions: potential implication in Alzheimer's disease pathology.

Correction: Detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of Alzheimer's disease.

Detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of alzheimer's disease.

Native PLGA nanoparticles regulate APP metabolism and protect neurons against β-amyloid toxicity: Potential significance in Alzheimer's disease pathology.

Unconjugated PLGA nanoparticles attenuate temperature-dependent β-amyloid aggregation and protect neurons against toxicity: implications for Alzheimer's disease pathology.